In AML, there are two different types of relevant mutations: class I mutations frequently result in uncontrolled proliferation and include receptor or cytoplasmatic–nuclear tyrosine kinase mutations such as FLT3, K/NRAS, TP53, and c-KIT, in 20–25%, 40%, 2%, and 12% cases, respectively, and do not affect differentiation. This evidence concerns the gene KIT and acute myeloid leukemia.